Join Dr Ankur Kalra in this episode of our mini-series, "Conversations about Hypertrophic Cardiomyopathy", as he engages in an in-depth discussion with Dr Carolyn Yung Ho. Together, they explore the journey from symptoms to diagnosis and management options for hypertrophic cardiomyopathy (HCM).
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
Dr Ho is Medical Director of the Cardiovascular Genetics Center and an Associate Professor at Harvard Medical School.
Dr Ho offers a comprehensive examination of HCM, providing valuable insights on diagnosing the condition and distinguishing it from other conditions. The discussion addresses important questions, such as when to refer patients suspected of having HCM.
The episode explores the significance of cardiac MRI in diagnosing and distinguishing HCM, with a focus on the distinctive features that aid in assessment. The differentiation between sarcomeric and non-sarcomeric forms of HCM is examined for its clinical relevance, with an emphasis on identifying individuals at risk.
Dr Ho sheds light on the diagnostic tools used for risk stratification in both obstructive and non-obstructive cases of HCM. The conversation delves into management strategies for non-obstructive HCM patients, including additional approaches to alleviate symptoms such as exertional dyspnoea.
The episode concludes by discussing cardiac myosin inhibition as a potential therapy, covering important considerations and providing a comprehensive checklist for initiating treatment. Additionally, the latest evidence on exercise training in HCM patients is highlighted.
Tune in to gain insights into the diagnosis and management of HCM as Dr Ankur Kalra and Dr Carolyn Yung Ho illuminate this intricate cardiovascular condition.
This content is intended for US-based physicians.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
Tune in to discover the strategies that Dr. Kalra and Dr. Alasnag are currently employing and gain insights into how these data will shape their future decision-making in the catheterization laboratory. Don't miss this informative discussion at the forefront of interventional cardiology.
As we adapt to the changes brought about by the pandemic, Dr Singh outlines the necessary steps to foster a reality in which we can utilize these technologies to create more time for human connection.
Dr Owens is Medical Director of the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the Hospital of the University of Pennsylvania.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
After the #MedBikini campaign provoked by a misogynistic study that scrutinized female doctors’ social media posts, this episode is about creating a safer environment for female healthcare professionals.
The charity organisation, Women as One is an agent for women and men to be part of medicine that is built on talent, rather than a privilege. Roxana and Ankur discuss the role of mentorship and family-friendly work environment in mending the broken house of cardiology. Roxana talks about the practical tools that are available for women to take the next steps in their career and achieve their goals.
Dr Kalra asks Dr Mauri about early influences and her traineeship with legendary interventionalists, the late Donald Baim and Richard Kuntz. Dr Mauri talks openly about her decision-making process and the importance of selecting your priorities and committing to them. Ankur asks Laura about her decision to go into industry. Laura shares her thoughts on medical innovations and meeting urgent needs with unique perspectives.
What is Dr Mauri’s advice for a young cardiologist? How did she balance research and patient care? What are the questions that helped her decision making? How does Dr Mauri think about innovations in medicine?